October 26, 2022
FDA: Class I recall of Jiangsu Well Biotech COVID-19 Ag Rapid Test
Editor's Note
The Food and Drug Administration (FDA) on October 12 identified the recall of Jiangsu Well Biotech’s COVID-19 Ag Rapid Test Devices as Class I, the most serious.
The recall was initiated because the tests were distributed to US customers without authorization, clearance, or approval from the FDA.
No complaints, injuries, or deaths have been reported.
Distribution dates were July 23, 2021 to January 23, 2022.
Free Daily News
- Study shows serious downside, risks to postop opioid prescription at discharge
- AAMI: Time, temperature, humidity affecting cleanliness of instruments, medical devices
- Anesthesiology research pipeline needs boost
- Assistance program leads to major drop in ER visits, costs for immigrants
- Anesthesia & Analgesia journal devotes October issue to DEI
- Long nursing shifts in mental health wards lead to increased patient incidents
- Closing keynote: Revolutionizing Healthcare with Artificial Intelligence (AI)—Reducing Administrative Burden and Improving Staff Satisfaction
- Postoperative session: PACU Boarding and Patient Experience—There are No Beds in the House!
- Leadership session: Empowering Your Team to Ensure Patient Safety
- ASC luncheon: Quality Measure Reporting Updates for ASCs
- Surgical Technician - FT 40 hours - OrthoVirginia - Lynchburg, VA
- Come join our amazing physician team in the beautiful Highlands of Maine! - Northern Light Health - Dover-Foxcroft, ME
- General Surgeons Needed in Presque Isle, Maine - Northern Light Health - Presque Isle, ME
- General Surgeon Opportunity in Beautiful Portland, Maine! - Northern Light Health - Portland, ME
© Access Intelligence, LLC. All rights reserved. | Privacy Policy | Diversity Inclusion & Equity